Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr Jones on Clinical Fracture Incidence in mHSPC

May 3rd 2023

Craig Jones, MBChB, discusses findings from an analysis of fracture incidence in patients with metastatic hormone-sensitive prostate cancer from the phase 2/3 STAMPEDE trial platform protocol.

Metastatic Hormone-Sensitive Prostate Cancer: Data from TITAN and PEACE-1

May 3rd 2023

Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.

Metastatic Hormone-Sensitive Prostate Cancer: Data From ENZAMET and ARCHES

May 3rd 2023

Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.

Apalutamide Plus ADT Improves PSA PFS in Biochemically Relapsed Prostate Cancer

May 2nd 2023

Apalutamide plus androgen deprivation therapy with or without abiraterone acetate and prednisone improved prostate-specific antigen progression-free survival in patients with biochemically relapsed prostate cancer, according to long-term follow-up data from the phase 3 PRESTO trial.

Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases

May 1st 2023

Centering discussion on a patient profile of mCRPC with asymptomatic bone metastases, experts share best approaches to treating and optimizing outcomes for such patients, including supplement recommendations to prevent bone fractures.

Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC

May 1st 2023

Drs Armstrong and Manning review the safety and efficacy data from the ALSYMPCA trial of radium-223 in patients with mCRPC.

Considerations for Treatment Selection for Patients with Disease Progression on Radium-223

May 1st 2023

A medical oncologist and radiation oncologist share clinical insight on how they might approach subsequent treatment selection in patients with mCRPC who have disease progression on or after radium-223.

Patient Profile: A 72-Year-Old Man with mCRPC and Multiple Bone Metastases

May 1st 2023

Radiation oncologist Matthew Manning, MD, shares the patient profile of a 72-year-old man with mCRPC receiving palliative treatment with radium-223.

Dr Lowentritt on PSA Response and Time to Castration Resistance in mCSPC

April 29th 2023

Benjamin H. Lowentritt, MD, FACS, discusses prostate-specific antigen response and time to castration resistance in patients with metastatic castration-sensitive prostate cancer started on apalutamide, enzalutamide, or abiraterone acetate.

Enzalutamide With or Without Leuprolide Offers MFS Benefit Vs Leuprolide Alone in nmHSPC With High-risk BCR

April 29th 2023

Treatment with the androgen receptor inhibitor enzalutamide plus leuprolide led to a significant reduction in the risk of metastasis or death compared with placebo plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Apalutamide Demonstrates Robust Real-World Effectiveness in mCSPC

April 29th 2023

Patients with metastatic castration-sensitive prostate cancer treated with the androgen receptor–signaling inhibitor apalutamide achieved prostate-specific antigen responses that trended higher and rates of progression to castration resistance that trended lower than those receiving enzalutamide or abiraterone acetate/

Darolutamide Plus ADT/Docetaxel Produces Durable PSA Responses in mHSPC

April 29th 2023

A post-hoc analysis of the phase 3 ARASENS trial demonstrated that the addition of darolutamide to androgen deprivation therapy and docetaxel produced deep and durable prostate-specific antigen responses in patients with metastatic hormone-sensitive prostate cancer.

Darolutamide Plus ADT Elicits OS Benefit in North American Patients With mHSPC

April 29th 2023

A subgroup analysis of the phase 3 ARASENS trial showed that darolutamide plus androgen deprivation therapy elicited an overall survival benefit in North American patients with metastatic hormone-sensitive prostate cancer.

Darolutamide Associated With Lower Rates of Treatment Discontinuation and Disease Progression in nmCRPC

April 29th 2023

Treatment with darolutamide was associated with lower rates of discontinuation and progression to metastatic disease compared with enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

FDA Panel Votes Proposed Olaparib/Abiraterone Indication Should Be Restricted to BRCA-Mutant mCRPC

April 28th 2023

In an 11-to-1 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the proposed indication of olaparib in combination with abiraterone acetate and prednisone or prednisolone for the initial treatment of patients with metastatic castration-resistant prostate cancer should be restricted to those whose tumors harbor a BRCA mutation.

Dr Liu on PSMA PET Imaging in Prostate Cancer

April 28th 2023

Jen-Jane Liu, MD, discusses the benefits of using prostate-specific membrane antigen PET imaging in the localized disease setting for patients with prostate cancer, the differences between PSMA PET and conventional imaging, and future considerations for effectively implementing this diagnostic approach in this population.

Frontline Olaparib Plus Abiraterone Reduces PSA Levels, Delays Time to PSA Progression in mCRPC

April 28th 2023

The addition of olaparib to abiraterone acetate resulted in numerically higher prostate-specific antigen response rates and prolonged time to PSA progression vs abiraterone alone when used in the frontline treatment of patients with metastatic castration-resistant prostate cancer.

Extended Darolutamide Demonstrates Long-term Safety, Clinical Benefit in Nonmetastatic CRPC

April 28th 2023

Darolutamide given in an extended duration was linked with long-term clinical benefit and safety in patients with nonmetastatic castration-resistant prostate cancer.

177Lu-PSMA-I&T Generates PSA Responses With Tolerable Safety in mCRPC

April 28th 2023

Treatment with lutetium 177 PSMA-I&T radioligand therapy led to prostate-specific antigen declines with an acceptable toxicity profile in patients with metastatic castration-resistant prostate cancer.

Dr Aggarwal on the Activity of BXCL701 Plus Pembrolizumab in SCNC mCRPC

April 26th 2023

Rahul Aggarwal, MD, discusses key findings from a phase 2a trial evaluating the combination of BXCL701 and pembrolizumab in patients with metastatic castration-resistant prostate cancer with the small cell neuroendocrine cancer phenotype.